Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathological, immunohistochemical and electron microscopical study

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1908-1915

  Nooijen, P T G A ^a   Manusama, E R ^b   Eggermont, A M M ^b   Schalkwijk, L ^a   Stavast, J ^b   Marquet, R L ^b   De Waal, R M W ^a   Ruiter, D J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Isolated limb perfusion; Melphalan; Platelets; Sarcoma; Tumour necrosis factor alpha

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER MODEL; CONTROLLED STUDY; DRUG POTENTIATION; EDEMA; ELECTRON MICROSCOPY; EXTRAVASATION; HISTOPATHOLOGY; HYPEREMIA; IMMUNOHISTOCHEMISTRY; LIMB PERFUSION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; SARCOMA; THROMBOCYTE AGGREGATION; TISSUE NECROSIS;

EID: 0030456873     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.652     Document Type: Article

References (32)

1. ALEXANDER RH, NELSON WG AND GOFFEY DS. (1987). Synergistic enhancement by tumour necrosis factor of in vitro eytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res., 47, 2403-2406.
2. ASHER A, MULÉ JJ, REICHERT CM, SHILONI E AND ROSENBERG SA. (1987). Studies on the anti-tumour efficacy of systemically administered recombinant tumour necrosis factor against several murine tumours in vivo. J. Immunol., 138, 963-974.
3. BAGHUS WM, JEUNINK MF, ROZING J AND ELEMA JW. (1989). A monoclonal antibody against rat platelets. I. Tissue distribution in vitro and in vivo. Clin. Exp. Immunol., 75 317-323.
4. BENCKHUIJSEN C, VAN DIJK WS AND VAN HET HOFF SC. (1982). High flow isolation perfusion of the rat hind limb in vivo. J. Surg. Oncol., 21, 249-257.
5. BERTOMEN MC, GALLO S, LAURI D, LEVINE, MN, ORR FW AND BUCHANAN MR. (1990). Chemotherapy enhances endothelial cell reactivity to platelets. Clin. Expl. Metastasis, 8, 511-518.
6. EGGERMONT AMM, LIÉNARD D, SCHRAFFORDT KOOPS H, ROSEN-KAIMER F AND LEUJEUNE FJ. (1993). Treatment of irresectable soft-tissue sarcomas of the limbs with high dose TNF-α in combination with interferon-γ and melphalan. In Tumour Necrosis Factor: Molecular und Cellular Biology and Clinical Relevance, Fiers W and Buurman W, (eds) pp. 219-243. Karger: Basle.
7. GERLACH H., LIBERMAN H, BACH R, GODMAN G, BRETT J AND STERN D. (1989). Enhanced responsiveness of endothelium in the growing, motile state to tumour necrosis factor/cachectin. J. Exp. Med., 170, 913-931.
8. GRAU GE, TACCHINI-COTTIER F, VESIN C, MILON G, LOU JN, PIGUET PF AND JUILLARD P. (1993). TNF-induced microvascular pathology: active role for platelets and importance of the LFA-1/CAM-1 interaction. Eur. Cytokine Netw., 4, 415-419.
9. JAIN RK. (1987a). Transport of molecules across tumor vasculature. Cancer Metastasis Rev., 6, 559-593.
10. JAIN RK. (1987b). Transport of molecules in the tumor interstitium: A review. Cancer Res., 47, 3039-3051.
11. KACHEL DL AND MARTIN WJ. (1994). Cyclophosphamide-induced lung toxicity: mechanisms of endothelial cell injury. J. Pharmacol. Exp. Ther., 268, 42-46.
12. DE KOSSODO S, MOORE R, GSCHMEISSNER S, EAST N, UPTON C AND BALKWILL FR. (1995). Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br. J. Cancer, 72, 1165-1172.
13. KUPER F, BLOKSMA N, BRUIJNTJES JP, HOFHUIS FMA AND WOLTERINK G. (1985). Effects of endotoxin-treatment on inflammatory cell infiltrates in murine meth-A sarcoma. J. Pathol., 147, 41-48.
14. KUPER F, BLOKSMA N AND HENDRIKSEN EGJ. (1986). Antitumour Effects of Endotoxin Against Solid Murine Meth A Tumours of Different Ages. II. Ultrastructure of Vascular and perivascular events. PhD thesis, State University Utrecht, The Netherlands.
15. LEJEUNE FJ. (1995). High dose recombinant tumour necrosis factor (rTNF-α) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer. Eur. J. Cancer, 31a 1009-1016.
16. LIÉNARD D, DELMOTTE JJ, RENARD N, EWALENKO P AND LEJEUNE FJ. (1992). High doses of rTNF-α in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10, 52-60.
17. LIÉNARD D, EGGERMONT AMM, SCHRAFFORDT KOOPS H, KROON BB, ROSENKAIMER E, AUTIER P AND LEJEUNE FJ. (1994). Isolated limb perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF alpha), interferon-gamma (INF-gamma) and melphalan for melanoma stage III. Results of a multi-center pilot study. Melanoma Res., 4 (suppl. 1), 21-26.
18. MACPHERSON GG AND NORTH RJ. (1986). Endotoxin mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology. Cancer Immunol. Immunother., 21, 209-216.
19. MANUSAMA ER, DURANTE NMC, MARQUET RL AND EGGERMONT AMM. (1994). Ischemia promotes the antitumour effect of tumour necrosis factor alpha (TNF-α) in isolated limb perfusion in the rat. Reg. Cancer Treat., 7, 155-159.
20. MANUSAMA ER, NOOIJEN PTGA, STAVAST J, DURANTE NMC, MARQUET RL AND EGGERMONT AMM. (1996). Synergistic antitumour effect of recombinant human tumour necrosis factor alpha (TNF-α) with melpahalan in isolated limb perfusion in the rat. Br. J. Surgery, 83, 551-555.
21. MARQUET RL, SCHELLEKENSH, WESTBROEK DL AND JEEKEL J. (1983). Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int. J. Cancer, 31, 223-226.
22. NAWROTH PD, HANDLEY H, BACH R, GODMAN G, BRETT J AND STERN D. (1989). Enhanced responsiveness of endothelium in the growing/motile state to tumour necrosis factor/cachectin. J. Exp. Med., 170, 913-931.
23. NOOIJEN PTGA, EGGERMONT AMM, VERBEEK MM, SCHALKWIJK L, BUURMAN WA, DE WAAL RMW AND RUITER DJ. (1996). Transient induction of E-selectin expression following TNF-α based isolated limb perfusion in melanoma and sarcoma patients is not tumour-specific. J. Immunother., 19(1), 33-44.
24. POSNER M, LIÉNARD D, LEJEUNE FJ, ROSENFELDER D AND KIRKWOOD J. (1994). Hyperthermic isolated limb perfusion (HILP) with tumour necrosis factor (TNF) alone for metastatic in transit melanoma. Proc. Am. Soc. Clin. Oncol., 13, 369.
25. PREHN RT AND MAIN JM. (1957). Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst., 18, 769-778.
26. REGENASS U, MÜLLER M, CURSCHELLAS E AND MATTER A. (1987). Anti-tumour effects of tumour necrosis factor in combination with chemotherapeutic agents. Int. J. Cancer, 39, 266-273.
27. RENARD N, LIÉNARD D, LESPAGNARD L, EGGERMONT AMM, HEIMANN R AND LEJEUNE FJ, (1994). Early endothelium activation and polymorphnuclear cell invasion precedes specific necrosis of human melamona and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int. J. Cancer, 57, 656-663.
28. RENARD N, NOOIJEN PTGA, SCHALKWIJK L, DE WAAL RMW, EGGERMONT AMM, LIÉNARD D, KROON BBR, LEJEUNE FJ AND RUITER DJ. (1995). VWF release and platelet aggregation in human melanoma after perfusion with TNF-α. J. Pathol., 176, 279-287.
29. SATO N, GOTO T, HARANAKA K, SATOMI N. NARIUCHI H, MANOHIRANO Y AND SASWASKI Y. (1986). Actions of tumour necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. Natl Cancer Inst., 76, 1113-1121.
30. SHIMOMURA K, MANDA T, MUKUMOTO S, KOBAYASHI K, NAHANO K AND MORI J. (1988). Recombinant human tumour necrosis factor-α: thrombus formation is a cause of anti-tumour activity. Int. J. Cancer, 41, 243-247.
31. WATANABE N, NIITSU Y AND UMENO H. (1988). Toxic effects of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48, 2197-2183.
32. WTEL VAN DE PA, BLOKSMA N, KUPER CF, HOFHUIS FMA AND WILLERS JMN. (1989). Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A Sarcoma, and relation to curative activity. J. Pathol., 157, 65-73.